Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy
September 25, 2015
???We see OGX-011 as a key component of our branded oncology medicines franchise, expanding our pipeline of existing oncology therapeutics and broadening the future available therapies made by Teva for oncology patients and care providers,??? said Moshe Manor, Teva's Group VP, Global Branded Products. ???OGX-011 is supported by compelling data demonstrating the drug??ôs ability to benefit patients on top of several currently available chemotherapies in a number of oncology indications. In addition to prostate cancer, we are particularly enthusiastic about the therapeutic activity seen in the Phase II clinical trial in lung cancer.???
???Together with Teva, we have forged a strong path moving forward for the development of OGX-011 that commits significant cash investment to a broadened Phase III clinical development plan that includes first- and second-line castrate resistant prostate cancer as well as non-small cell lung cancer,??? said Scott Cormack, President and CEO of OncoGenex. ???The agreement provides us with capital resources for the development of OGX-011 through completion of the Phase III clinical trials and into product commercialization. We??ôre creating a solid foundation to maximize the broad potential of OGX-011 and bring this important treatment option to cancer patients.???SOURCE Teva Pharmaceutical Industries Ltd, OncoGenex Pharmaceuticals